パートナー
製薬、化学、バイオテクノロジー技術に関する米国地方裁判所特許訴訟を専門とする。訴訟経験は幅広く、これまで特許権者及び特許権侵害被疑者双方の側に立ち、特許侵害、企業秘密の不正利用、商標、著作権等あらゆる種類の訴訟を全ての訴訟段階で手掛けている。弊所東京オフィスのパートナーとして4年間日本に駐在していた。
国内外のクライアントに対する戦略的ポートフォリオ管理及び訴訟カウンセリングを提供し、M&Aやインライセンス契約の機会に伴う企業の特許ポートフォリオ評価も行っている。特許侵害訴訟準備として、特許侵害、有効性、執行可能性に関する鑑定書も作成。さらに、クライアントに対し将来の訴訟を見据えた、効果的な特許ポートフォリオの発展、出願上の具体的問題への対応、クレーム戦略に関するアドバイスを提供している。
重要な医薬品に関する世界規模の特許ポートフォリオの戦略的管理を実施。革新的製薬会社の代理人としてデューデリジェンスにおいて、ライセンス契約及び共同開発契約の締結又は有利な買収、また1000万ドル以上の買収を勝ち取る等の成功に導いている。
国内外で特許法に関する講義を定期的に行っており、法律および科学技術に関する多数の論文を執筆している。さらに、次のような国際プログラムで数多くの講演を行っている;AIPPI(国際知的財産保護協会)、シンガポール・ソウル;LexisNexis、深セン市;日本ライセンス協会、東京;JIPA(日本知的財産協会)、東京・大阪・四国;「Managing Intellectual Property」のラウンドテーブルディスカッション、東京。発表のトピックは、米国での訴訟戦略、ディスカバリー、グローバル規模でのフォーラム・ショピング、差し止め、日本と米国双方の自明性基準比較、幹細胞技術の特許性、効果的デューデリジェンス戦略、米国特許商標庁への出願を権利化まで効果的に導く方法、等多岐に渡る。
Managing Intellectual Property誌により、米国ジョージア州における “IP Star”に選出。また、Legal Media Group社のGuide to the World’s Leading Patent Law Practitioners で2016年以来米国特許弁護士ランキングの上位に入賞している。
Successfully represented Nissei ASB in a patent infringement, breach of contract, tortious interference with business relations, and trade secret misappropriation litigation related to blow mold machines used to manufacture containers for consumer product packaging.
4:19-cv-00042, W.D. Mo., Judge Kays
Successfully represented Ajinomoto in an ITC investigation and IPR proceedings involving patents related to genetically modified organisms and the use thereof to make commercial quantities of tryptophan. The ITC’s final determination found the Ajinomoto patents not invalid and infringed, and the ITC issued limited exclusion and cease-and-desist orders barring CJ and other respondents from importing infringing products for sale in the United States. The PTAB denied institution of CJ’s petitions on both challenged patents.
337-TA-1005, ITC, Judges Bullock, Essex
IPR2017-01551, -01698, PTAB, Judges Franklin, Mitchell, Moore, Sawert, Yang
1:14-cv-00664, D. Del., Judge Sleet
IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney
1:08-md-01949, D. Del., Judges Farnan, Stark
10-1460, -1461, -1462, -1463, -1464, -1465, -1466, -1467, -1468, -1469, -1470, -1471, -1472, -1473, Fed. Cir., Judges Mayer, Newman, Plager
Successfully represented Kissei and Allergan in district court Hatch-Waxman litigation related to Rapaflo® (silodosin) for benign prostatic hyperplasia.
1:17-cv-01161, D. Del., Judge Stark
3:15-cv-00668, D.N.J., Judges Goodman, Sheridan
3:12-cv-07907, D.N.J., Judges Goodman, Hillman, Williams, Wolfson
Successfully led Kaken and Bausch Health Care in inter partes review (IPR) proceedings, district court litigation, and Federal Circuit appeal related to patent covering Kaken and Bausch Health Care’s Jublia® (efinaconazole) product for the treatment of onychomycosis.
3:18-cv-13635, D.N.J., Judges Martinotti, Goodman
18-2232, Fed. Cir., Judges Newman, O'Malley, Taranto
IPR2017-00190, PTAB, Judges Mitchell, Franklin, Pollock
IPR2017-01429, PTAB, Judges Mitchell, Franklin, Pollock
1:18-cv-00664, D. Del., Judge Andrews
1:16-cv-03498, S.D.N.Y., Judges Gorenstein, Vyskocil
337-TA-1005, ITC, Judges Bullock, Essex
18-1590, -1629, Fed. Cir., Judges Dyk, Moore, Taranto
IPR2017-01551, -01698, PTAB, Judges Franklin, Mitchell, Moore, Sawert, Yang
1:10-cv-00915, D. Del., Judge Stark
5:03-cv-00887, C.D. Cal., Judges Pfaelzer, Timlin, Abrams, Larson
1:03-cv-04904, N.D. Ill., Judge Gottschall
1:04-mc-00038, N.D. Ohio, Judge Polster
C.A. No. 20069, Del. Ch., Judge Lamb
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Leads district court litigation for Novartis against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer.
1:21-cv-00870, D. Del., Judge Hall
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Led Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc.
Represented AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against Zydus on its blockbuster Farxiga® pharmaceutical drug product. After a bench trial, Judge Andrews ruled that the defendant failed to prove that any of the patent claims at issue were invalid due to obviousness, resulting in a complete win for our client. That decision was not ultimately appealed.
1:18-cv-00664, D. Del., Judge Andrews
Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al.
Lead counsel for Ajinomoto in the Southern District of New York in litigation involving patents related to genetically modified organisms and the use thereof to make commercial quantities of tryptophan. The case settled following successful representation of Ajinomoto in related inter partes review (IPR) proceedings, an ITC investigation, and a subsequent Federal Circuit appeal.
1:16-cv-03498, S.D.N.Y., Judges Gorenstein, Vyskocil
337-TA-1005, ITC, Judges Bullock, Essex
18-1590, -1629, Fed. Cir., Judges Dyk, Moore, Taranto
IPR2017-01551, -01698, PTAB, Judges Franklin, Mitchell, Moore, Sawert, Yang
AstraZeneca AB v. Aurobindo Pharma, Ltd.
Successfully represented AstraZeneca in Abbreviated New Drug Application (ANDA) litigation and inter partes review (IPR) proceedings against multiple generic challengers on its Onglyza® and Kombiglyze® XR pharmaceutical drug products. Patent validity upheld in both the district court and parallel IPR proceeding.
1:14-cv-00664, D. Del., Judge Sleet
IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney
Kaken Pharmaceutical Co., Ltd.; Bausch Health Care v. Zydus Pharmaceuticals (USA) Inc. et al.
Successfully led Kaken and Bausch Health Care in inter partes review (IPR) proceedings, district court litigation, and Federal Circuit appeal related to patent covering Kaken and Bausch Health Care’s Jublia® (efinaconazole) product for the treatment of onychomycosis.
3:18-cv-13635, D.N.J., Judges Martinotti, Goodman
18-2232, Fed. Cir., Judges Newman, O'Malley, Taranto
IPR2017-00190, PTAB, Judges Mitchell, Franklin, Pollock
IPR2017-01429, PTAB, Judges Mitchell, Franklin, Pollock
Event
Discovery in U.S. Patent Litigation & Managing its Potential Impact in Related Foreign Cases Discovery in U.S. Patent Litigation & Managing its Potential Impact in Related Foreign Cases
January 18, 2023
Webinar
Event
Patent Infringement After Duncan Parking Technologies Patent Infringement After Duncan Parking Technologies
September 29, 2022
Webinar
Event
19th Advanced Summit on Life Sciences Patents 19th Advanced Summit on Life Sciences Patents
July 21-22, 2021
Virtual
Podcasts
Patent Strategy in the Life Sciences Industry Patent Strategy in the Life Sciences Industry
November 10, 2020
Legal Media GroupConference
18th Advanced Virtual Summit on Life Sciences Patents 18th Advanced Virtual Summit on Life Sciences Patents
August 5-6, 2020
Virtual
"John Livingstone brings an international outlook and inspires confidence in his clients as a skilled litigator, prudent counsellor and post-grant proceedings ace."
Intellectual Asset Management Patent 1000
“The top name on the fight card locally is John Livingstone, who is also one of the firm’s best Hatch-Waxman Act litigators.”
Intellectual Asset Management Patent 1000
“…comfortable in any forum, John Livingstone takes on the toughest life sciences and chemical cases with zeal. Having worked for several years in Finnegan’s Tokyo office, he has cultivated a strong following of Japanese innovators…”
Intellectual Asset Management Patent 1000
“… John Livingstone [is] singled out by peers for [his] IP capabilities. Livingstone, former leader of the firm's biotechnology practice in Japan, runs a U.S. district court patent litigation practice that specializes in pharmaceuticals, chemicals, and biotechnology.”
Managing Intellectual Property IP Stars
“Atlanta's John Livingstone 'always has the best interest of his client in mind.’”
Legal 500 United States
“One client lauded the work of John Livingstone, describing him as ‘a very smart and reliable attorney who shows a deep understanding of internal business documents.’”
Managing Intellectual Property IP Stars
“Livingstone’s practice primarily emphasizes U.S. district court litigation related to pharmaceutical, chemical, and biotechnology. Clients rave about the partner…”
Managing Intellectual Property IP Stars
“Litigator John Livingstone ‘always thinks what is best for his client,’ says a biotech contact.”
Managing Intellectual Property’s IP Stars
“John Livingstone and David Weingarten are other compelling advocates, particularly in the context of major pharmaceutical and biotechnology cases.”
Intellectual Asset Management Patent 1000
"John Livingstone brings an international outlook and inspires confidence in his clients as a skilled litigator, prudent counsellor and post-grant proceedings ace."
Intellectual Asset Management Patent 1000
“The top name on the fight card locally is John Livingstone, who is also one of the firm’s best Hatch-Waxman Act litigators.”
Intellectual Asset Management Patent 1000
“…comfortable in any forum, John Livingstone takes on the toughest life sciences and chemical cases with zeal. Having worked for several years in Finnegan’s Tokyo office, he has cultivated a strong following of Japanese innovators…”
Intellectual Asset Management Patent 1000
“… John Livingstone [is] singled out by peers for [his] IP capabilities. Livingstone, former leader of the firm's biotechnology practice in Japan, runs a U.S. district court patent litigation practice that specializes in pharmaceuticals, chemicals, and biotechnology.”
Managing Intellectual Property IP Stars
“Atlanta's John Livingstone 'always has the best interest of his client in mind.’”
Legal 500 United States
“One client lauded the work of John Livingstone, describing him as ‘a very smart and reliable attorney who shows a deep understanding of internal business documents.’”
Managing Intellectual Property IP Stars
“Livingstone’s practice primarily emphasizes U.S. district court litigation related to pharmaceutical, chemical, and biotechnology. Clients rave about the partner…”
Managing Intellectual Property IP Stars
“Litigator John Livingstone ‘always thinks what is best for his client,’ says a biotech contact.”
Managing Intellectual Property’s IP Stars
“John Livingstone and David Weingarten are other compelling advocates, particularly in the context of major pharmaceutical and biotechnology cases.”
Intellectual Asset Management Patent 1000
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Benchmark LitigationAward/Ranking
Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings
September 21, 2023
LMG Life SciencesPress Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersAward/Ranking
Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023 Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023
July 25, 2023
LMG Life SciencesPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset ManagementDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.